Overview

Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly

Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of repeated subcutaneous (under the skin) injections at different doses of BIM 23A760 on growth hormone and insulin-like growth factor-1 levels in patients with acromegaly after 6 months of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
Dopamine
Somatostatin